INLYTA for Malignant urinary tract neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 7 adverse event reports in the FDA FAERS database where INLYTA was used for Malignant urinary tract neoplasm.
Most Reported Side Effects for INLYTA
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 97 | 19.2% | 30 | 10 |
| Diarrhoea | 96 | 19.0% | 7 | 11 |
| Death | 75 | 14.8% | 75 | 4 |
| Fatigue | 68 | 13.4% | 3 | 8 |
| Nausea | 45 | 8.9% | 3 | 5 |
| Renal cancer | 45 | 8.9% | 6 | 4 |
| Dysphonia | 40 | 7.9% | 0 | 5 |
| Decreased appetite | 33 | 6.5% | 3 | 5 |
| Asthenia | 29 | 5.7% | 4 | 8 |
| Hypertension | 26 | 5.1% | 1 | 7 |
| Vomiting | 26 | 5.1% | 4 | 4 |
| Weight decreased | 26 | 5.1% | 3 | 2 |
| Blood pressure increased | 22 | 4.4% | 0 | 3 |
| Constipation | 22 | 4.4% | 0 | 0 |
| Pain in extremity | 21 | 4.2% | 1 | 3 |
Other Indications for INLYTA
Renal cancer (236)
Renal cell carcinoma (71)
Metastatic renal cell carcinoma (46)
Renal cancer metastatic (22)
Neoplasm malignant (15)
Other Drugs Used for Malignant urinary tract neoplasm
BEVACIZUMAB (156)
PAZOPANIB (97)
ERLOTINIB (75)
ATEZOLIZUMAB (73)
CABOZANTINIB S-MALATE (31)
SUNITINIB MALATE (28)
AXITINIB (23)
EVEROLIMUS (13)
PEMBROLIZUMAB (11)
SUTENT (9)